Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats

Deepthi Alapati, Min Rong, Shaoyi Chen, Dorothy Hehre, Maria Rodriguez, Kenneth E. Lipson, Shu Wu

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Despite recent advances in neonatal intensive care and surfactant therapy, bronchopulmonary dysplasia (BPD) continues to be one of the most common long-term pulmonary complications associated with preterm birth. Clinical efforts to prevent and treat BPD have been largely unsuccessful due to itsmultifactorial nature and poorly understood disease process. Connective tissue growth factor (CTGF) is a matricellular protein that plays an important role in tissue development and remodeling. Previous studies have demonstrated that hyperoxia exposure up-regulates CTGF expression in neonatal rat lungs. Whether CTGF overexpression plays a role in the pathogenesis of BPD, and whether CTGF antagonism has a therapeutic potential for BPD, are unknown. In the present study, we examined CTGF expression in lung autopsy specimens from patients with BPD and control subjects with no BPD. We assessed the effect of a CTGF-neutralizing monoclonal antibody (CTGF Ab) on preventing hyperoxia-induced lung injury in neonatal rats. Our study demonstrates that CTGF expression is increased in BPD lungs. In newborn rats, exposure to 90% oxygen for 14 days resulted inactivation of β-catenin signaling, decreased alveolarization and vascular development, and physiological and histological evidence of pulmonary hypertension (PH). However, treatment with CTGF Ab prevented β-catenin signaling activation, improved alveolarization and vascular development, and attenuated PH during hyperoxia. These data indicate that CTGF-β-catenin signaling plays a critical role in the pathogenesis of experimental BPD. CTGF antagonism may offer a novel therapeutic strategy to alleviate BPD and PH in neonates.

Original languageEnglish
Pages (from-to)1169-1177
Number of pages9
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume45
Issue number6
DOIs
StatePublished - Dec 1 2011

Fingerprint

Connective Tissue Growth Factor
Hyperoxia
Bronchopulmonary Dysplasia
Lung Injury
Rats
Antibodies
Catenins
Pulmonary Hypertension
Therapeutics
Lung
Blood Vessels
Neonatal Intensive Care
Premature Birth
Neutralizing Antibodies
Surface-Active Agents
Autopsy
Up-Regulation
Chemical activation
Monoclonal Antibodies
Newborn Infant

Keywords

  • Alveolarization
  • BPD
  • CTGF
  • Pulmonary hypertension
  • Vascularization

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats. / Alapati, Deepthi; Rong, Min; Chen, Shaoyi; Hehre, Dorothy; Rodriguez, Maria; Lipson, Kenneth E.; Wu, Shu.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 45, No. 6, 01.12.2011, p. 1169-1177.

Research output: Contribution to journalArticle

Alapati, Deepthi ; Rong, Min ; Chen, Shaoyi ; Hehre, Dorothy ; Rodriguez, Maria ; Lipson, Kenneth E. ; Wu, Shu. / Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats. In: American Journal of Respiratory Cell and Molecular Biology. 2011 ; Vol. 45, No. 6. pp. 1169-1177.
@article{a109baa7fdd94ab78ee3fb87d691ee14,
title = "Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats",
abstract = "Despite recent advances in neonatal intensive care and surfactant therapy, bronchopulmonary dysplasia (BPD) continues to be one of the most common long-term pulmonary complications associated with preterm birth. Clinical efforts to prevent and treat BPD have been largely unsuccessful due to itsmultifactorial nature and poorly understood disease process. Connective tissue growth factor (CTGF) is a matricellular protein that plays an important role in tissue development and remodeling. Previous studies have demonstrated that hyperoxia exposure up-regulates CTGF expression in neonatal rat lungs. Whether CTGF overexpression plays a role in the pathogenesis of BPD, and whether CTGF antagonism has a therapeutic potential for BPD, are unknown. In the present study, we examined CTGF expression in lung autopsy specimens from patients with BPD and control subjects with no BPD. We assessed the effect of a CTGF-neutralizing monoclonal antibody (CTGF Ab) on preventing hyperoxia-induced lung injury in neonatal rats. Our study demonstrates that CTGF expression is increased in BPD lungs. In newborn rats, exposure to 90{\%} oxygen for 14 days resulted inactivation of β-catenin signaling, decreased alveolarization and vascular development, and physiological and histological evidence of pulmonary hypertension (PH). However, treatment with CTGF Ab prevented β-catenin signaling activation, improved alveolarization and vascular development, and attenuated PH during hyperoxia. These data indicate that CTGF-β-catenin signaling plays a critical role in the pathogenesis of experimental BPD. CTGF antagonism may offer a novel therapeutic strategy to alleviate BPD and PH in neonates.",
keywords = "Alveolarization, BPD, CTGF, Pulmonary hypertension, Vascularization",
author = "Deepthi Alapati and Min Rong and Shaoyi Chen and Dorothy Hehre and Maria Rodriguez and Lipson, {Kenneth E.} and Shu Wu",
year = "2011",
month = "12",
day = "1",
doi = "10.1165/rcmb.2011-0023OC",
language = "English",
volume = "45",
pages = "1169--1177",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Connective tissue growth factor antibody therapy attenuates hyperoxia-induced lung injury in neonatal rats

AU - Alapati, Deepthi

AU - Rong, Min

AU - Chen, Shaoyi

AU - Hehre, Dorothy

AU - Rodriguez, Maria

AU - Lipson, Kenneth E.

AU - Wu, Shu

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Despite recent advances in neonatal intensive care and surfactant therapy, bronchopulmonary dysplasia (BPD) continues to be one of the most common long-term pulmonary complications associated with preterm birth. Clinical efforts to prevent and treat BPD have been largely unsuccessful due to itsmultifactorial nature and poorly understood disease process. Connective tissue growth factor (CTGF) is a matricellular protein that plays an important role in tissue development and remodeling. Previous studies have demonstrated that hyperoxia exposure up-regulates CTGF expression in neonatal rat lungs. Whether CTGF overexpression plays a role in the pathogenesis of BPD, and whether CTGF antagonism has a therapeutic potential for BPD, are unknown. In the present study, we examined CTGF expression in lung autopsy specimens from patients with BPD and control subjects with no BPD. We assessed the effect of a CTGF-neutralizing monoclonal antibody (CTGF Ab) on preventing hyperoxia-induced lung injury in neonatal rats. Our study demonstrates that CTGF expression is increased in BPD lungs. In newborn rats, exposure to 90% oxygen for 14 days resulted inactivation of β-catenin signaling, decreased alveolarization and vascular development, and physiological and histological evidence of pulmonary hypertension (PH). However, treatment with CTGF Ab prevented β-catenin signaling activation, improved alveolarization and vascular development, and attenuated PH during hyperoxia. These data indicate that CTGF-β-catenin signaling plays a critical role in the pathogenesis of experimental BPD. CTGF antagonism may offer a novel therapeutic strategy to alleviate BPD and PH in neonates.

AB - Despite recent advances in neonatal intensive care and surfactant therapy, bronchopulmonary dysplasia (BPD) continues to be one of the most common long-term pulmonary complications associated with preterm birth. Clinical efforts to prevent and treat BPD have been largely unsuccessful due to itsmultifactorial nature and poorly understood disease process. Connective tissue growth factor (CTGF) is a matricellular protein that plays an important role in tissue development and remodeling. Previous studies have demonstrated that hyperoxia exposure up-regulates CTGF expression in neonatal rat lungs. Whether CTGF overexpression plays a role in the pathogenesis of BPD, and whether CTGF antagonism has a therapeutic potential for BPD, are unknown. In the present study, we examined CTGF expression in lung autopsy specimens from patients with BPD and control subjects with no BPD. We assessed the effect of a CTGF-neutralizing monoclonal antibody (CTGF Ab) on preventing hyperoxia-induced lung injury in neonatal rats. Our study demonstrates that CTGF expression is increased in BPD lungs. In newborn rats, exposure to 90% oxygen for 14 days resulted inactivation of β-catenin signaling, decreased alveolarization and vascular development, and physiological and histological evidence of pulmonary hypertension (PH). However, treatment with CTGF Ab prevented β-catenin signaling activation, improved alveolarization and vascular development, and attenuated PH during hyperoxia. These data indicate that CTGF-β-catenin signaling plays a critical role in the pathogenesis of experimental BPD. CTGF antagonism may offer a novel therapeutic strategy to alleviate BPD and PH in neonates.

KW - Alveolarization

KW - BPD

KW - CTGF

KW - Pulmonary hypertension

KW - Vascularization

UR - http://www.scopus.com/inward/record.url?scp=82755165212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755165212&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2011-0023OC

DO - 10.1165/rcmb.2011-0023OC

M3 - Article

C2 - 21659659

AN - SCOPUS:82755165212

VL - 45

SP - 1169

EP - 1177

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 6

ER -